The simultaneous administration of MUC1 mRNA and CTLA-4-targeting siRNA represents a dual immunotherapeutic strategy aimed at overcoming the immunologically “cold” tumor microenvironment characteristic of TNBC, a context in which such combined approaches have been explored only to a limited extent. The gene discussed is CTLA4; the disease is neoplasm.